Jan Nilsson tell us about the future among other things in an interview with Finwire

About CombiGene AB

CombiGene’s vision is to provide patients affected by severe diseases with the prospect of a better life through gene therapy and other forms of advanced treatments.
Our business has three focus areas: sourcing of new and promising assets, development of these assets to proof of concept under our management and expertise, and outlicensing of the assets to a strategic partner for continued development and commercialization. Revenue is achieved through milestone payments and royalties.

The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market. The company’s Certified Adviser is Västra Hamnen Corporate Finance AB.

CombiGene AB
Agavägen 52A
SE-181 55 Lidingö
Sweden

info@combigene.com

Follow what's happening at CombiGene, sign up to receive news from us.

Our privacy policy

We use cookies to ensure that we give you the best experience on our website. If you continue to use this website, we will assume that you accept it.Ok Privacy policy